xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.
Company profile
Ticker
XOMA, XOMAP, XOMAO
Exchange
Website
CEO
James Neal
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
XOMA CORP /DE/, XOMA LTD /DE/
SEC CIK
Corporate docs
Subsidiaries
XOMA Technology Ltd. • XOMA (US) LLC • XOMA UK Limited • XRL 1 LLC ...
IRS number
942756657
XOMA stock data
Latest filings (excl ownership)
8-K
Other Events
25 Apr 24
8-K
Completion of Acquisition or Disposition of Assets
3 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
3 Apr 24
ARS
2023 FY
Annual report to shareholders
2 Apr 24
DEFA14A
Additional proxy soliciting materials
2 Apr 24
DEF 14A
Definitive proxy
2 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
19 Mar 24
S-4
Registration of securities issued in business combination transactions
11 Mar 24
S-3
Shelf registration
8 Mar 24
10-K
2023 FY
Annual report
8 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.47 mm | 33.47 mm | 33.47 mm | 33.47 mm | 33.47 mm | 33.47 mm |
Cash burn (monthly) | (no burn) | 3.73 mm | 1.93 mm | 2.34 mm | 699.67 k | 1.51 mm |
Cash used (since last report) | n/a | 25.72 mm | 13.29 mm | 16.14 mm | 4.82 mm | 10.40 mm |
Cash remaining | n/a | 7.75 mm | 20.19 mm | 17.33 mm | 28.65 mm | 23.07 mm |
Runway (months of cash) | n/a | 2.1 | 10.5 | 7.4 | 41.0 | 15.3 |
Institutional ownership, Q2 2023
99.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 15 |
Closed positions | 6 |
Increased positions | 19 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 135.55 bn |
Total shares | 11.57 mm |
Total puts | 2.30 k |
Total calls | 11.40 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BVF | 3.63 mm | $68.64 bn |
Biotechnology Value Fund L P | 3.53 mm | $144.08 mm |
FMR | 1.18 mm | $22.36 bn |
NVS Novartis | 539.13 k | $8.76 mm |
BLK Blackrock | 428.74 k | $8.10 bn |
Vanguard | 411.41 k | $7.77 bn |
Stonepine Capital Management | 349.40 k | $6.60 bn |
Opaleye Management | 275.00 k | $594.75 mm |
Geode Capital Management | 153.90 k | $2.91 bn |
Acuitas Investments | 137.13 k | $2.59 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Jan 24 | Owen Hughes | Performance Stock Units Common Stock | Grant | Acquire A | No | No | 0 | 275,000 | 0.00 | 275,000 |
3 Oct 23 | Bradley Sitko | Common Stock | Buy | Acquire P | No | No | 13.89 | 250 | 3.47 k | 5,600 |
2 Oct 23 | Bradley Sitko | Common Stock | Buy | Acquire P | No | No | 14.25 | 1,500 | 21.38 k | 5,350 |
2 Oct 23 | Owen Hughes | Common Stock | Buy | Acquire P | No | No | 13.83 | 1,000 | 13.83 k | 3,500 |
26 Sep 23 | Owen Hughes | Common Stock | Buy | Acquire P | No | No | 14.43 | 2,499 | 36.06 k | 2,500 |
25 Sep 23 | Owen Hughes | Common Stock | Buy | Acquire P | No | No | 14.65 | 1 | 14.65 | 1 |
31 May 23 | Bradley Sitko | Common Stock | Buy | Acquire P | Yes | No | 17.2 | 1,000 | 17.20 k | 3,500 |
31 May 23 | Bradley Sitko | Common Stock | Buy | Acquire P | Yes | No | 17 | 500 | 8.50 k | 2,500 |
News
HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target
25 Apr 24
XOMA Corp Entered Into A Merger Agreement To Acquire Kinnate Biopharma For A Base Cash Price Per Share Of $2.3352 Per Share And An Additional Cash Amount Of Not More Than $0.2527 Per Share
19 Mar 24
HC Wainwright & Co. Maintains Buy on XOMA, Maintains $74 Price Target
11 Mar 24
Recap: XOMA Q4 Earnings
8 Mar 24
XOMA FY GAAP EPS $(4.04) May Not Be Comparable To $(2.05) Estimate, Sales $4.76M Miss $6.50M Estimate
8 Mar 24
Press releases
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
25 Apr 24
Actym Therapeutics Appoints Thomas Smart as CEO
24 Apr 24
XOMA Declares Quarterly Preferred Stock Dividends
21 Mar 24
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE
13 Mar 24
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
8 Mar 24